SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
5.52
-0.04 (-0.72%)
Mar 6, 2026, 3:33 PM EST - Market open
SciSparc Employees
SciSparc had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
$653,000
Profits / Employee
-$3,240,000
Market Cap
3.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Artelo Biosciences | 5 |
| Oragenics | 5 |
| GRI Bio | 4 |
| 60 Degrees Pharmaceuticals | 3 |
SPRC News
- 4 days ago - SciSparc Announces 1-for-9 Reverse Share Split - GlobeNewsWire
- 4 weeks ago - SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA - GlobeNewsWire
- 4 weeks ago - Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA - TheNewswire
- 5 weeks ago - SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization - GlobeNewsWire
- 7 weeks ago - SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - GlobeNewsWire
- 7 weeks ago - SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance - GlobeNewsWire
- 2 months ago - Neurothera Labs Announces Results of AGM - TheNewswire
- 2 months ago - SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - GlobeNewsWire